Nature biomedical engineeringApr 24, 2026

DeepDrugDiscovery finds substances that boost cell cleaning and can cross into the brain for Alzheimer's disease

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 27, 2026

Abstract

Essence

DeepDrugDiscovery prioritized brain-penetrant, mTOR-independent autophagy enhancers that improved Alzheimer's disease model phenotypes.

Evidence

A platform and preclinical validation study combined AI screening with worm and mouse Alzheimer's disease model tests of two lead compounds for blood-brain barrier crossing, aggregate clearance, and memory restoration.

Caveat

The evidence remains from computational screening plus animal disease models, not human clinical testing of efficacy, dosing, or safety.

Simplified

Dysfunctional autophagy, a key cellular cleaning process, is a key driver of brain ageing and neurodegenerative diseases such as Alzheimer's disease (AD). However, developing effective treatments by enhancing autophagy has been challenging, as most known compounds act through the broad mTOR pathway, risking side effects, and few can effectively penetrate the brain. To address this, we developed DeepDrugDiscovery-a mechanism-aware, AI-powered screening platform incorporating ADMET and blood-brain barrier penetrability predictions. Here we show that this platform successfully identified novel, mTOR-independent autophagy enhancers, with two lead compounds demonstrating an ability to cross the blood-brain barrier, clear AD-related protein aggregates and restore memory function in worm and mouse AD models. By releasing DeepDrugDiscovery as an open-source, modular tool, we offer a user-friendly AI platform that enables customized therapeutic screening. Our work establishes a scalable, AI-driven pipeline that integrates cross-species validation to rapidly discover mechanism-based therapeutics for diseases with high unmet medical need.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Evandro F Fang disclosed ownership, agreements, and consulting relationships involving MindRank AI and other named organizations; 8 other authors were described as employers of MindRank AI.

PubMed

Featured in

Longevity & AgingIssue #34

Anti-aging drug fisetin reverses blood vessel dysfunction in old mice by targeting senescent cells

↗

DeepDrugDiscovery finds substances that boost cell cleaning and can cross into the brain for Alzheimer's disease

Abstract

Full Text

Funding

Competing interests

Featured in

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief